ReviewClinical rheumatology2015
Treatment of osteoporosis in renal insufficiency.
Review in Clinical rheumatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 23 citations in OpenAlex.
- Assessing osteopenia and osteoporosis with dual-energy x-ray absorptiometry studies in Fabry disease.Orphanet journal of rare diseases · 2025Article
- Perioperative risk factors for osteoporosis after radical gastrectomy for gastric cancer.BMC surgery · 2024Article
- Osteoporosis in children and adolescents: when to suspect and how to diagnose it.European journal of pediatrics · 2022Review
- Bisphosphonates and bone mineral density in patients with end-stage kidney disease and renal transplants: A 15-year single-centre experience.Bone reports · 2022Article
- Effects of parathyroidectomy on plasma PTH fragments and heart rate variability in stage 5 chronic kidney disease patients.Renal failure · 2021Article
- Bisphosphonate nephropathy: A case series and review of the literature.British journal of clinical pharmacology · 2021Review
- [Treatment of rheumatic disease with renal insufficiency].Der Orthopade · 2019Review
- Management of Osteoporosis in Chronic Kidney Disease.Internal medicine (Tokyo, Japan) · 2017Review
- Osteoprotegerin and uremic osteoporosis in chronic hemodialysis patients.International urology and nephrology · 2017Article
- Osteoporosis in the adult solid organ transplant population: underlying mechanisms and available treatment options.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2016Review
- Macrophages: Their Emerging Roles in Bone.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2015Review
- [Dosage and toxicity of antirheumatic drugs in renal insufficiency].Zeitschrift fur Rheumatologie · 2015Review
- Multiple fractures and impaired bone metabolism in Wolfram syndrome: a case report.Clinical cases in mineral and bone metabolism : the official journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal DiseasesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with osteoporosis often have chronic kidney disease (CKD). CKD is associated with bone and mineral disturbances, renal osteodystrophy, which like osteoporosis leads to a higher risk of fractures. Bisphosphonates are first-line therapy for osteoporosis; however, these are contra-indicated in patients with a GFR <30 ml/min. In this article, we have reviewed the diagnosis and treatment of osteoporosis in moderate to severe renal failure from data of clinical trials. Results have shown that osteoporosis patients and severe CKD with no signs of renal osteodystrophy, oral bisphosphonates (risedronate) seem to be a safe choice. Renal function and PTH should subsequently be monitored strictly. Denosumab, with regularly monitoring of calcium and adequate vitamin D levels or raloxifene are a possible second choice. In any case, one should be certain that there is no adynamic bone before treatment can be started. If there is any doubt, bone biopsies should be taken.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.